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doi:10.1016/j.bpg.2011.02.012In the last years, several studies have been performed with the aim
to evaluate the real impact of antiviral treatments on ﬁbrosis
progression in patients with chronic viral hepatitis.
The main goal of therapy in patients with chronic hepatitis B is
viral suppression. This outcome leads to an important improve-
ment in both hepatic inﬂammation and ﬁbrosis and reduces the
HCC occurrence. An histological improvement has been largely
demonstrated in patient treated with oral nucleoside and nucle-
otide analogs achieving the rate of 72% with entecavir and
tenofovir.
Similarly, in patients with chronic hepatitis C, sustained virologic
response to interferon therapy is associated with regression of
ﬁbrosis and lower liver decompensation and HCC occurrence.
In the next future further studies will assess the real impact of the
new directly anti-viral agents on liver necroinﬂammation and
ﬁbrosis in chronic hepatitis C.
 2011 Elsevier Ltd. All rights reserved.Introduction
Liver ﬁbrosis is a common complication of chronic viral hepatitis leading to the progressive
destruction of normal tissue architecture or the replacement of hepatocytic tissue with ﬁbrous tissue.
The ﬁnal outcome of this process is liver cirrhosis, which is the major cause of morbidity and mortality
in chronic viral hepatitis. Fibrogenesis is closely related to activation of the main type of ﬁbro-
competent cells in the liver: hepatic stellate cells. Experimental models have allowed a better
understanding of the dynamics of ﬁbrosis, the biological processes related to its progression and
regression and the development of new anti-ﬁbrotic drugs. However, the role of interferon-based andfax: þ39 0916552156.
so).
d. All rights reserved.
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chronic viral hepatitis on ﬁbrosis progression in comparison with the natural history of these disease
remain an important issue to assess. This review collects the literature data published so far.
Chronic HBV infection
Epidemiology and incidence of ﬁbrotic evolution to cirrhosis
Between 350 million and 400 million persons worldwide are chronically infected with hepatitis B
virus (HBV) [1]. The two primary adverse outcomes of chronic infection are hepatocellular carcinoma
(HCC) and cirrhosis, either of which can lead to a liver-related death. The annual incidence of cirrhosis
in patients with CHB has been estimated at 1.3–2.4% [2] and although the cumulative 5-year survival
rate for patients with compensated cirrhosis is 84% [3], in patients with decompensated cirrhosis, this
declines to 14–35% [3,4].
A number of studies have examined predictors of progression to advanced ﬁbrosis [5–9] and
considerable attention has been focused on a large, prospective recent study of the incidence of cirrhosis
in CHB [10]. This study followed 3582 subjects for a mean of 11 years and reported that cirrhosis was
strongly correlated with the level of circulating virus, with an increasing incidence of cirrhosis being
found in patients with higher levels of virus at entry into this study. It should be noted that 85% of this
cohort was HbeAg-negative and this study was restricted to patients over 30 years of age.
The current literature in HBeAg-positive patients does not support an association between HBV
DNA and ﬁbrosis. Two studies of over 300 predominantly HBeAg-positive patients did not ﬁnd HBV
DNA to be a predictor of ﬁbrosis [11,12], suggesting that lower HBV DNA, reﬂecting an increased
immune response, is correlated with ﬁbrosis.
Similar results have been found by Wang et al [13] who studied 28 HBeAg-positive, immune-
tolerant patients and reported that lower serum HBV DNA level, along with age 430 years, was
independently correlated with stage 2 ﬁbrosis or more on liver biopsy.
Mechanisms and features of ﬁbrosis
In chronic HBV infection, liver damage appears to be immune-mediated, with HBV-speciﬁc T cells
playing a key role both in disease pathogenesis and viral clearance. The inﬂammatory inﬁltrates of
chronic hepatitis B shows similar cellular composition of the chronic hepatitis C, with CD4-positive T
cells predominating over CD8-positive T cells [14].
When the HBV-speciﬁc CD8 response is unable to control virus replication, it may contribute to liver
pathology not only directly, but also by causing recruitment of non–virus-speciﬁc T cells [15] which
have an aberrant functional proﬁle and may impede proliferative anti-viral effector function, while
contributing to the proinﬂammatory cytokine environment [16]. Furthermore, NK cells may also cause
hepatocyte death by a non–antigenspeciﬁc mechanism [17].
In chronic hepatitis B, there is a varying degree of predominantly lymphocytic portal inﬂammation
with interface hepatitis and spotty lobular inﬂammation.
Inﬂammation isminimal in the immune-tolerant and inactive carrier phases, but is prominent in the
immunereactive phase. Bridging necrosis is identiﬁed as inﬂammation ‘connecting’ portal tracts to one
another or to central veins and conﬂuent necrosis affects multiple contiguous hepatocytes. Inﬂamma-
tion is typically associated with scarring, which can vary from a mild portal expansion to periportal
ﬁbrous strands, bridging ﬁbrosis, and cirrhosis. A typical histological feature of chronic hepatitis B is
‘ground-glass’ cytoplasm of the hepatocytes rich in hepatitis B surface antigen (HBsAg) [18].
Impact of HBeAg seroconversion to Anti-HBe on liver ﬁbrosis
The loss of HBeAg is associated with a fall in HBV DNA to low levels (generally<1000 IU/mL),
normalization of serum ALT levels, and resolution of active necroinﬂammatory injury on liver biopsy.
Histological studies based on paired biopsies obtained before and after HBeAg seroconversion have
consistently demonstrated that seroconversion to antibody to HBeAg (anti-HBe) is followed by
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irrespective of the extent of the liver damage in the baseline biopsy, indicating that liver histology
during the HBeAg-positive phase is not predictive of the late outcome of liver disease [19]. When
sustained, these changes are associated with excellent long-term prognosis [20]. Unfortunately, loss of
HBeAg with or without HBeAg seroconversion is not always associated with resolution of disease.
Infact, in some patients, HBeAg reappears in the serum once treatment is withdrawn and the disease
returns to its initial level of activity. In other patients, virological, biochemical, and clinical relapse of
disease occurs without reappearance of HBeAg (HBeAg-negative chronic hepatitis B), which may be as
severe as HBeAg-positive disease.
Relapse in disease either due to return of HBeAg or evolution into HBeAg-negative hepatitis appears
to be more common in responders to oral nucleoside analogue therapy than in those responding to
interferon or peginterferon and recent data suggest that a fall in HBeAg concentration during pegin-
terferon therapy predicts subsequent HBeAg loss [21].
Impact of Serum HBV DNA suppression
Serum HBV DNA levels reﬂect the level of hepatic HBV replication but do not necessarily indicate
the presence of ongoing HBV-related liver injury.
However, the observation that patients in with HBV DNA concentrations >105 copies/mL
(w20,000 IU/mL) were at increased risk of HCC (odds ratio ¼ 8.9) has led some to suggest that viral
suppression should be themain goal of therapy for all patients, irrespective of other factors [22]. Infact,
with suppression of viral replication, liver biochemistry, and more importantly, histology, both
inﬂammation and ﬁbrosis improve.
Mechanisms and impact of anti-viral treatment
In chronic hepatitis B, complete eradication of hepatitis B virus (HBV) infection is rarely achieved
with currently available therapies. Even in those who clear HBsAg, HBV remains in infected hepato-
cytes in the form of covalently closed circular DNA (cccDNA) likely for the lifetime of the cell if not the
individual, thus making it possible for reactivation to occur with the right stimulus [23].
Thus, the goal of therapy is to prevent the development of cirrhosis that greatly increases the risk of
HCC and the other complications of advanced liver disease. However the progression to these clinically
relevant endpoints is slow, generally requiring years or decades to become evident and then they are
impractical targets to assess therapy. Thus potential therapeutic surrogate endpoints include clinical,
biochemical, virological, serological, or histological improvement.
Alpha interferon beneﬁts
Alpha interferon acts by inducing an anti-viral state in cells, through engagement of cell surface
receptors and subsequent activation of pathways that lead to increased expression of intracellular
genes that cause an increase in breakdown in viral RNAs and protection against viral injury [24].
Alpha interferon also stimulates cell-mediated immune responses which target infected hepato-
cytes leading to a decrease in cells that harbour the intrahepatic, HBV covalently closed circular DNA
(cccDNA) molecules responsible for persistence of HBV infection.
In the last years there has been an increased interest based on results demonstrating the pegin-
terferon has more potent anti-viral activity than standard alpha interferon and, in contrast to nucle-
oside analogues, does not result in anti-viral resistance and can be given for a ﬁnite period rather than
indeﬁnitely [25].
Three large clinical trials of peginterferon have convincingly demonstrated that a loss of HBsAg
after anti-viral therapy was conﬁned to patients receiving peginterferon, either alone or in combina-
tion [26–28].
HBsAg clearance has been reported to occur less commonly in HBeAg-negative hepatitis, reﬂecting
the generally lower rates of sustained virological response with this disorder and perhaps differences
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those who are HBeAg-positive [29,30].Analogues Therapy Beneﬁts
The use of oral nucleoside and nucleotide analogues have revolutionized the management of
chronic hepatitis B. Five different anti-viral agents have been approved and the treatment with these
oral agents has been shown to be life-saving.
Such therapy can not only retard the progression of ﬁbrosis and reverse both ﬁbrosis and cirrhosis
[31–36], but also salvage patients with decompensated chronic hepatitis B [37–39] and prevent hepatic
decompensation in patients with advanced ﬁbrosis and cirrhosis [40].
Lamivudine
Lamivudine is the ﬁrst oral agent licensed for treatment of hepatitis B. Clinical trials have been
shown that Lamivudine therapy is able to retard the progression of ﬁbrosis, reduce progression to and
reverse cirrhosis, salvage and stabilize patients with hepatic decompensation (delaying or averting
liver transplantation), and, in patients with advanced ﬁbrosis and cirrhosis, to prevent hepatic
decompensation [31,34,37,38,40].
Although lamivudine has the most extensive safety record, its current use is limited by the high
frequency of lamivudine resistance (up to 30% in year 1 and up to70%by the end of 5 years) [41] and the
availability of more potent agents with superior efﬁcacy and markedly improved resistance proﬁles.
Adefovir
Adefovir is less potent than lamivudine and the other more recently introduced oral agents but the
advantage of this drug is its limited resistance during 1–2 years, the absence of cross-resistance with
lamivudine and other L-nucleosides and, therefore, its value as treatment for lamivudine-resistant
chronic hepatitis B [42,43] and for hepatic decompensation associated with lamivudine resistance
prior to and after liver transplantation [44].
Moreover, although resistance to adefovir is slow to emerge, resistant variants increase progres-
sively after the ﬁrst year, reaching almost 30% by the end of 4 years [45].
Entecavir
Entecavir inhibits HBV DNA priming, reverse transcription of negative stranded HBV DNA and
synthesis of positive-strand HBV DNA and has profound activity against HBV. Therapy with entecavir
was associated with a more frequent fall of HBV DNA to undetectable levels (<102 log10 copies/mL)
than lamivudine, in 67% versus 36% of patients who were HBeAg-positive and in 90% versus 72% in
patients who were HBeAg-negative.
Histological improvement was achieved in 72% of entecavir-treated patients compared to 62% in
lamivudine-treated patients with HBeAg; and in 70% of entecavir-treated versus 62% of lamivudine-
treated patients in those who were HBeAg-negative [46,47].
Recently, the impact on liver inﬂammation and ﬁbrosis in patients who received at least 3 years of
cumulative entecavir therapy has been evaluated. The authors found that 96% of the patients with CHB
who were treated with entecavir in this long-term cohort achieved substantial histological improve-
ment and regression of ﬁbrosis or cirrhosis [48].
Telbivudine
There is a paucity of data on the real effects of telbivudine on histological improvement in patients
with chronic hepatitis B. In HBeAg-positive patients, telbivudine seems to be superior to lamivudine in
suppressing HBV DNA to undetectable levels, < 102 copies/mL (60% versus 40%), and in achieving
histological improvement (65% versus 56%) but not in biochemical (77% versus75%) or serological
responses (HBeAg seroconversion in 23% versus 22%). However, in HBeAg-negative patients, telbivu-
dine was superior to lamivudine in suppressing HBV DNA to undetectable levels (88% versus 71%) but
not in achieving histological (67% versus 66%) or biochemical improvement (74% versus 79%) [49].
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Tenofovir is themost recently approved drug for hepatitis B and at recommended oral doses is more
potent, more rapidly acting, and has a better resistance proﬁle and an excellent safety proﬁle than
adefovir [50].
Licensed initially for the treatment of human immunodeﬁciency virus (HIV), either as mono-
therapy or in a single–pill combination with emtricitabine, tenofovir has excellent anti-viral activity
against hepatitis B in patients with HIV/HBV coinfection as well as in patients with HBV
monoinfection.
One of the most important advantages of this drug is the HBsAg seroconversion obtained in 3% of
patients during the ﬁrst 48 weeks of therapy [50] which increased, at the end of year 2 of continuous
tenofovir treatment, to 6% [51]. In HBeAg-negative patients, at the end of year 1 of therapy, tenofovir
suppressed HBV DNA to <102 IU/mL in 95% of patients, compared to 64% in the adefovir group and
histological improvement was observed in 72% of the tenofovir-treated subjects. Also for tenofovir,
further studies will assess the real impact of this ‘newer’ oral agent on liver ﬁbrosis related to HBV.
Chronic HCV infection
Epidemiology and incidence of progression to cirrhosis
In the Western world HCV infection is the major cause of cirrhosis and hepatocellular carcinoma
(HCC), the main cause of liver-related deaths and themost common indication for liver transplantation
(OLT) [52–56]. There are approximately 170 million carriers of chronic HCV worldwide, but probably
most of them are not identiﬁed [57]. Among patients, more than 30million are affected by cirrhosis and
about 1–2 million new HCC cases are discovered each year.
Although a test for HCV was available since 1989 [58], the natural history of this chronic infection is
only partially understood, and its evolution to liver cirrhosis is very variable.
Many factors, either virus-related or host-related, have been investigated in order to understand the
natural history of this infection. The biochemistry is only partially indicative of the evolution because
chronic infection could develop with abnormal alanine aminotransferase (ALT) levels in 60%–80% of
cases and among subjects with normal ALT levels in 20%–40%. In a study on HCV-infected patients with
persistently normal aminotransferases levels and mild hepatitis, the biopsy performed after ﬁve years
showed no progression [59]. About 30%–50% of all infected patients develop hepatic ﬁbrosis without
clinically and biochemically signiﬁcant liver disease. As far as the factors related to the virus are
concerned, genotype does not correlatewith the activity of the disease [60], nor with the outcome [61],
although an Italian study found a signiﬁcant correlation between genotype 1b and risk of HCC [62].
Viral load has no correlation with the histology activity index although it has implications on viral
response to anti-viral therapy. However, the presence of other viral infections, like HIV/HBV, speeds up
the clinical course of the disease [63–65].
Among the host-related factors, age at infection [66–68], male gender, race, and alcohol
consumption of more than 50 gm/day are statistically associated with ﬁbrosis progression [68–70].
Another important aspect that impacts on the evolution of chronic HCV infection is the presence of co-
morbidities. Obesity, iron overload, environmental factors and non-alcoholic steatohepatitis are
important determinants of disease progression [71–75]. Among investigated co-factors determining
the natural history of the infection, alcohol is undoubtedly the most relevant risk factor of progression
to cirrhosis [76]. There are also geographical differences in the evolution to cirrhosis: in U.S.A. and
Europe this percentage is nearly 15% (range 8%–24%), while in Japan is much higher, ranging between
30% and 46%. Similarly, the percentage of evolution to HCC is 0.7%–1.3% inWestern countries, but in the
Far East and Japan the rate is ranges from 10% to 19%.
As a matter of fact the most important information comes from studies performed on infection
acquired after blood transfusions or after injection with contaminated immunoglobulins. Studies
dealing with community-acquired infection could be the most important ones, but the absence of
data on the onset of the infection makes it very difﬁcult to outline the true timetable of events. Long-
term studies in patients with transfusion-acquired infection indicate that spontaneous recovery
occurs in 12%–26% of cases, chronic hepatitis in 40%–73%, cirrhosis in 15%–23%, and liver-related
death after 25 years of follow-up is 4% (range 3%–7%). In these patients, the time interval between the
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10, 20 and 30 years, respectively [58,77,78]. The very prolonged course of disease does not allow to
assess directly the true endpoints of therapeutic anti-viral efﬁcacy, such as increased survival,
therefore, the stable disappearance of indicators of the HCV infection and of necroinﬂammatory/
ﬁbrogenetic process in the liver is assumed to represent the cure of the disease and is used to the best
surrogate endpoint.
Histological lesions provide direct evidence of the activity grade and the ﬁbrosis stage and its trend
to progression towards cirrhosis.
Impact of anti-viral treatment on progression of chronic hepatitis C to cirrhosis
Liver biopsy is the best standard to assess the severity of chronic hepatitis C, to deﬁne the prognosis
and to assess the necroinﬂammation or the ﬁbrosis modiﬁcations. The comparison of histological
activity and the stage of ﬁbrosis on biopsies performed before and after anti-viral treatment remains
the most reliable parameter to assess short-term beneﬁt of viral clearance [79]. A study from Japan
examined whether interferon therapy was associated with regression of histological ﬁbrosis in 487
patients by using paired biopsy samples obtained 1–10 years apart [80]. The results suggest that, in
patients with chronic hepatitis C, regression of ﬁbrosis is associated with sustained virologic response
to interferon therapy. Another European study which analyzed the long-term clinical outcome of
chronic hepatitis C patients with sustained virological response concluded that sustained virological
response was associated with a decrease in ﬁbrosis score [81]. Similar ﬁndings have been reported in
sustained responders to pegylated interferon [82,83]. Recently, another study has been performedwith
the aim to evaluate the long-term histologic outcome of people with SVR after HCV therapy in a large
cohort of patients [84]. The authors found that 82% of the patients had decreased ﬁbrosis scores, and
92% had decreased inﬂammation scores on long-term follow-up biopsies, concluding that clinical,
virologic, biochemical, and histologic outcomes of patients followed 5 years after SVR are favourable,
and recovery of normal or nearly normal liver architecture is possible.
To better deﬁne the long-term beneﬁts of anti-viral therapy, we must take into account the
likelihood of progression to cirrhosis in treated patients. Available literature data on this issue are
scarce [81,85,86]. Once SVR is achieved after anti-viral therapy, histological progression is
uncommon (7 out of 1660, 0.43%). Instead, in relapsers or non-responders to anti-viral therapy the
rate of disease evolution to cirrhosis over 1–13 years is much more frequent (162 out of 2078,
7.7%).
Impact of anti-viral treatment on progression from compensated to decompensated cirrhosis and
hepatocellular carcinoma
Many studies sought to investigate whether SVR, compared to no response, leads to an improved
clinical outcome for patients with chronic hepatitis C and advanced ﬁbrosis.
A cohort study concluded that patients with CHC and advanced ﬁbrosis, SVR reduced complications
of liver disease, especially development of liver failure [87], but a signiﬁcant decrease in incidence of
HCC has not found. These ﬁndings contrasts with results of studies from Japan, where the beneﬁt of
interferon treatment lies mainly in the prevention of HCC [88,89].
A randomised controlled trial (RCT) comparing pegylated interferon monotherapy vs. combina-
tion therapy with ribavirin in patients with HCV cirrhosis and portal hypertension to assessed the
efﬁcacy and feasibility of anti-viral therapy and explored the role of viral eradication on the clinical
course of disease [90]. It has been found that overall rate of SVR was higher in the group of patients
receiving ribavirin, although the result was not statistically signiﬁcant due to inadequate sample size,
and it has been concluded that viral eradication was related to a marked improvement in prognosis,
since disease deterioration occurred only in 6% of patients with SVR as compared to 38% of non-
responders [90].
Bruno et al [91] in a recent study demonstrated that the achievement of SVR abolishes the devel-
opment of EV in the long-term. These data are also supported by other studies in which the
achievement of virological response following anti-viral therapy was associated with a signiﬁcant
decrease of HVPG values [92,93], ﬁbrosis regression [94,95], and reduction of portal hypertension–
related complications in patients with similar clinical characteristics [87,96].
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Cardoso et al [97] in a cohort of 307 patients with bridging ﬁbrosis or cirrhosis HCV-related.
Viral hepatitis and HIV coinfection
Hepatitis C virus (HCV) and/or hepatitis B virus (HBV) coinfection is a common ﬁnding in HIV-
infected individuals [98].
Recently the use of highly active antiretroviral therapy (HAART) has led to a much longer survival of
these patients, and to the emergence of different causes of death, including end-stage liver disease [99].
It is a well-known fact that HIV infection exacerbates the natural history of HCV infection [100,101].
HIV-infected patients are less likely to clear hepatitis C viraemia following acute infection, have
higher HCV RNA loads, and experience more rapid progression of HCV-related liver disease than those
without HIV infection [98].
A meta-analysis of multiple studies assessed the correlation between HIV coinfection and the
progression of HCV-related liver disease, ﬁnding a signiﬁcant higher risk of developing cirrhosis and
end-stage liver disease when compared with HCV monoinfection [102].
Recent observations have shown the possible direct ﬁbrogenic action of an HIV envelope protein
and this indicates an additional mechanism providing a novel molecular basis for the strong clinical
evidence linking HIV/HCV coinfection with accelerated ﬁbrogenesis.
Bruno et al [103] have recently demonstrated that gp120 exerts proﬁbrogenic action on human
HSCs in culture, identifying a direct pathway possibly linking HIV infection with liver ﬁbrogenesis via
envelope proteins. These data open up new perspectives for the management of liver diseases in HCV/
HIV-co-infected patients.
The natural history of HBV infection is also modiﬁed by HIV coinfection, which can result in higher
rates of HBV persistence (HBsAg, HBeAg, and HBV DNA detection), HBV relapse (reemergence of HBsAg,
HBeAg, or HBV DNA) and increased risk of liver-related morbidity and mortality [104–106].
Impact of AART on liver ﬁbrosis in coinfected patients
HCV
Studies on the effect of ART on the natural history of chronic HCV disease have been contradictory
[107,108]. Qurishi et al reported a lower risk of liver mortality in persons who lived long enough to
receive effective ART [109]. However, several prospective studies have not detected a beneﬁcial effect
of ART on HCV disease [110,111].
In other studies, ART has been associated with hepatic injury (e.g., hepatocellular necrosis and
steatosis) [112,113]. Indeed, in a large cohort of HIV-infected patients, Weber et al observed an
increased risk of liver-related mortality with longer ART exposure [114].
In some studies, the risk of ART-associated hepatotoxicity is greater in coinfected persons with
advanced hepatic ﬁbrosis, suggesting that liver disease staging prior to initiating ART may be useful to
stratify the risk of hepatotoxicity [115].
Interestingly, effective treatment of HCV infection has been associated with reduced risk of ART-
associated liver injury [116].
HBV
The effect of antiretroviral-related immune restoration has been associated with spontaneous
recovery from chronic HBV infection but, in other studies, with ﬂares of hepatitis B. More recently,
Puoti and coworkers observed that exposure to lamivudine containing ART has associated with
decreased risk of liver-related death in w2000 HBV/HIV coinfected persons [117]. Similarly, Miailhes
and colleagues reported that 12 of 82 coinfected persons who received ART experienced seroconver-
sion to anti-HBe and/or anti-HBs [118]. While there are emerging data to suggest that antiretroviral
regimens that contain drugs active against HBV infection (e.g.tenofovir, emtricitabine, and lamivudine)
may modify the natural history of HBV disease in HIV-infected persons by slowing disease progression
and, in some patients, leading to seroconversion, additional long-term follow-up is needed to evaluate
the effect of dual treatment.
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The evaluation of liver ﬁbrosis and its staging is essential in the management of chronic viral
hepatitis. Indeed, liver biopsy is currently required before starting anti-viral therapy. Furthermore. the
histological evaluation of ﬁbrosis and necroinﬂammation has been used for the evaluation of impact of
anti-viral therapy on liver damage.
Available evidence indicates the important role of anti-viral treatment on the improvement of
histological ﬁndings in patients with chronic viral hepatitis.
In chronic HBV setting, seroconversion to antibody to HBeAg (anti-HBe) and suppression of viral
replication are followed by a signiﬁcant improvement of disease activity and ﬁbrosis. HBsAg loss
during Interferon based therapy is a clinically important event that is associated with improved
survival and a lower risk for hepatocellular carcinoma in patients with cirrhosis. Histological
improvement is obtained with all analogues treatment, achieving the value of 72% with entecavir
and tenofovir.
The objective of therapy in patients with chronic hepatitis C is hence to inhibit viral replication in
order to decrease liver necroinﬂammation, which in turn is directly related to development of cirrhosis
and occurrence of HCC.
This reviews shows that the beneﬁt of interferon treatment on ﬁbrosis progression is clinically
signiﬁcant in patients with advanced ﬁbrosis by the reduction of ﬁbrosis progression to cirrhosis.
Patients treated with IFN based therapy showed a signiﬁcant reduction in the rate of progression to
cirrhosis and development of HCC in sustained viral responders as compared to non-responders or
relapsers.
In the next future the use of the new promising directly anti-viral agents may represent an
important perspective for the treatment of chronic hepatits C and more data on the impact of these
drugs on liver necroinﬂammation and ﬁbrosis will be available in the next years.Practice points
 HBsAg loss is a clinically important event that is associated with improved survival and
a lower risk for hepatocellular carcinoma in patients with cirrhosis.
 Treatment with oral analogues retard the progression of ﬁbrosis, reverse both ﬁbrosis and
cirrhosis, salvage patients with decompensated chronic hepatitis B and prevent hepatic
decompensation in patients with advanced ﬁbrosis and cirrhosis.
 In chronic hepatitis B, even clearing HBsAg, HBV remains in infected hepatocytes in the form
of covalently closed circular DNA (cccDNA) for the lifetime thus making it possible for
reactivation to occur.
 In patients with chronic hepatitis C, obesity, iron overload, environmental factors and NASH
are important determinants of disease progression.
 In chronic hepatitis C, regression of ﬁbrosis is associated with sustained virologic response to
interferon therapy.
 HIV-infected patients are less likely to clear hepatitis C viraemia following acute infection,
have higher HCV RNA loads, and experience more rapid progression of HCV-related liver
disease than those without HIV infection.
Research agenda
 Prospective controlled studies are necessary to deﬁne the controversial association between
hepatitis B virus (HBV) mutations and progression of ﬁbrosis and hepatocarcinogenesis.
 In the next years, further studies should be performed in order to assess the impact of the
new directly anti-viral agents on liver necroinﬂammation and ﬁbrosis in chronic hepatitis C.
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